240 results about "Antigen epitope" patented technology

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention provides a disease marker epitope prediction and antibody screening method, which belongs to the technical field of disease markers, and comprises the following steps: firstly, establishing a training data set containing a known antigen-antibody compound structure and disease tissue expression data; and obtaining target protein sequence information through liquid chromatography-mass spectrometry analysis and carrying out sequence comparison. And then a deep convolutional neural network is utilized to extract sequence features, and surface exposure sites are identified by combining secondary structure prediction and solvent accessibility analysis. After the features are integrated with sequence evolution conservative properties, a prediction model is constructed by using a random forest classifier. The method comprises the following steps: carrying out molecular dynamics simulation on a prediction result, screening first 10% of candidate sequences through a comprehensive scoring function and K-means clustering, and finally determining an antigen epitope sequence with the strongest binding activity through verification of an antigen chip and a fluorescence labeled antibody system, so that the technical problem that specific antigen epitopes are difficult to accurately predict and recognize in the prior art is solved.

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The invention belongs to the technical field of biological detection, and particularly relates to a specific monoclonal antibody for AKK bacterium active protein P9, a detection kit and application of the specific monoclonal antibody. The antibody pair is 7G4 and 8B2, the amino acid sequence of a heavy chain variable region of the 7G4 is SEQ ID NO.2, and the amino acid sequence of a light chain variable region of the 7G4 is SEQ ID NO.4; the amino acid sequence of the 8B2 heavy chain variable region is SEQ ID NO.6, and the amino acid sequence of the 8B2 light chain variable region is SEQ ID NO.8. The antibody pair has strong specificity and high affinity, and can accurately recognize different antigen epitopes of the P9 protein. A colloidal gold detection and double-antibody sandwich ELISA detection system constructed based on the kit adapts to a complex matrix and various process treatment samples, is stable and reliable in detection, has qualitative and quantitative capabilities, can be used for scenes of P9 protein detection, fermentation monitoring, quality control and the like, and solves the problems of insufficient specificity, poor adaptability and the like in the prior art.

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The invention discloses a monoclonal antibody of feline herpesvirus gB protein, an antigen epitope peptide recognized by the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody of the feline herpesvirus gB protein comprises an antibody heavy chain and an antibody light chain, wherein a variable region of the antibody light chain comprises a CDR1 consisting of an amino acid sequence as shown in SEQ ID NO.1, a CDR2 of which the amino acid sequence is QVS and a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO.3; a variable region of the antibody heavy chain comprises a CDR1 composed of an amino acid sequence shown in SEQ ID NO.4, a CDR2 composed of an amino acid sequence shown in SEQ ID NO.2 and a CDR3 composed of an amino acid sequence shown in SEQ ID NO.5. According to the research, one specific monoclonal antibody is successfully prepared and obtained, the antigen epitope recognized by the specific monoclonal antibody is identified, and a biological foundation is laid for developing a specific detection reagent of FHV-1.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The invention relates to a pTau antigen compound of an AP205 or Lus protein nanoparticle carrier, a vaccine containing the pTau antigen compound as well as a preparation method and application of the pTau antigen compound. According to the pTau antigen compound disclosed by the invention, pTau antigen epitope peptide is efficiently loaded on a protein nanoparticle carrier by utilizing a specific SpyCatcher-SpyTag biological coupling system and is self-assembled to form a 180 / 60 polymer spherical structure, so that the pTau antigen epitope peptide is displayed on the surface of the spherical structure to form an ordered and repeated antigen array; therefore, an organism can be stimulated to generate specific immune response aiming at pTau protein to the greatest extent, and the immunogenicity is relatively high; the vaccine based on the pTau antigen compound can induce an organism to generate a high-titer pTau antibody, and cannot induce generation of T cell reaction aiming at pTau, so that the vaccine has relatively high safety.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

The present application relates to a 48E-scFv-Fc recombinant antibody with broad-spectrum activity against waterfowl parvovirus, a construction method and application thereof, the 48E-scFv-Fc recombinant antibody comprising a light chain variable region and a heavy chain variable region, and the amino acid sequences of the light chain variable region and the heavy chain variable region are shown as SEQ ID NO: 1-2. The present application provides a coding gene for encoding the recombinant antibody, which comprises a DNA sequence shown as SEQ ID NO: 3-4. The present application also provides a corresponding recombinant plasmid and a preparation method of the 48E-scFv-Fc recombinant antibody, etc. The 48E-scFv-Fc recombinant antibody can simultaneously recognize four waterfowl parvoviruses of cGPV, MDPV, MDGPV and SBDSV, and has a good application prospect in immunological detection of waterfowl parvovirus infection, antigen epitope research, passive immunization preparation development and broad-spectrum antibody drug research, etc.

The invention relates to the technical field of biology, in particular to a helicobacter pylori antibody typing reagent combination as well as a preparation method and application of the helicobacter pylori antibody typing reagent combination. Comprising an acridinium ester mouse anti-human IgG complex solution, a biotin-Ure recombinant protein complex solution, a biotin-CVfp fusion protein complex solution and a streptavidin magnetic bead mother solution. The biotin-Ure recombinant protein complex liquid is obtained by labeling Ure recombinant protein with biotin, and the amino acid sequence of the Ure recombinant protein is as shown in SEQ ID No. 1; the biotin-CVfp fusion protein complex liquid is obtained by labeling CVfp fusion protein with biotin, the CVfp fusion protein carries out fusion expression on antigen epitopes of CagA and VacA, and the amino acid sequence of the CVfp fusion protein is shown as SEQ ID No.2. The problems that at present, Hp virulence factor typing detection indexes are complex, reagent cost is high, and detection flux is low are solved.

The invention relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody. The amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.2, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.3. Meanwhile, the invention provides the PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is as shown in SEQ ID NO. 4. According to the research, on the basis that the PRV strain TK protein is successfully expressed, the PRV strain TK protein is purified to serve as an antigen to immunize a mouse, the specific monoclonal antibody aiming at the PRV strain TK protein is prepared by utilizing a hybridoma technology, and an important tool is provided for PRV epidemic strain TK protein structure and function research and subsequent establishment of a PRV specific diagnosis method and related research.

The present application relates to the technical field of biological medicine, in particular to an aptamer for simultaneously simulating free and combined Neu5Gc, a kit and application thereof.The nucleotide sequence of the aptamer is shown as SEQ ID No.1.The aptamer provided by the present application can effectively simulate free and various combined Neu5Gc antigen epitopes, can be combined with more kinds of anti-Neu5Gc antibodies compared with the existing limited kinds of antigens, can detect the content of anti-Neu5Gc antibodies in serum and related preparations as a molecular probe, and the detected content is closer to the real level, can detect the content of Neu5Gc antigens in biological preparations through the competition principle, and is expected to be used as a Neu5Gc substitute for in-vivo experiments due to its low immunogenicity.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The invention discloses a feline leukemia virus p27 protein monoclonal antibody, a hybridoma cell strain and application thereof, and relates to the technical field of biology, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1 in a sequence table, and the amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.2 in the sequence table. According to the invention, a cell fusion technology is utilized to establish a hybridoma cell strain p27-3A5 capable of secreting a p27 protein monoclonal antibody, and a specific monoclonal antibody 3A5 is obtained. And the minimum linear epitope identified by the antibody is identified, so that the establishment of subsequent preparation of a diagnostic kit such as a colloidal gold test strip is facilitated.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

The invention discloses a polyclonal antibody targeting a human CPNE7 variable splicing isomer and application of the polyclonal antibody, and belongs to the technical field of biological medicine. The antigen epitope 'KYKQKRRSYKN' (SEQ ID NO.1) capable of being targeted by the polyclonal antibody provided by the invention is positioned in a common conserved region of all main isomers of CPNE7, and a variable splicing region is not involved. The titer of the obtained antibody serum is as high as 1: 32,000, which indicates that the antibody has extremely high immunoreactivity and sensitivity and can be used for detecting trace proteins. The antibody disclosed by the invention can be used for effectively identifying GST-CPNE7 fusion protein expressed by a prokaryotic system and CPNE7-FL and CPNE7-S protein overexpressed in an eukaryotic system (A549 cells), and the applicability of the antibody in various experimental systems is proved. Therefore, the blank in the prior art can be filled, and a core tool is provided for research of the CPNE7 in the fields of tumor biology, diagnosis and treatment.

We provide antigen-based immunotherapy, particularly cancer immunotherapy. [Solution] The present invention provides antigenic peptides that are different from human tumor antigen epitopes but have amino acid similarities thereto, and in particular share the same core sequence. The present invention further provides immunogenic compounds, nanoparticles, cells, and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.

The invention discloses a low-sensitivity whitening recombinant humanized collagen composition and a preparation method thereof. The low-sensitivity whitening recombinant humanized collagen composition is prepared from modified recombinant humanized collagen, tetrahydrocurcumin, ethyl ascorbic acid ether and dipotassium glycyrrhizinate, the modified recombinant humanized collagen comprises a recombinant humanized collagen chain segment, a polyethylene glycol chain segment modified on the recombinant humanized collagen chain segment, and tetrahydromethyl pyrimidine formyl modified at the other end of the polyethylene glycol chain segment. The modified recombinant humanized collagen can provide proper steric hindrance to achieve the effects of shielding residual antigen epitopes and improving the efficiency of combining target spot cell surface receptors, and cooperates with other mild whitening components to act on various pathways (including oxidation resistance, transport inhibition, enzyme inhibition and inflammation resistance), so that synergistic interaction and irritant hedging are realized, and the skin whitening effect is improved. Therefore, the whitening effect is achieved under low skin irritation.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

The application relates to an antibody sequence design method based on a given antigen-antibody complex structure. The method comprises a. a modeling stage, which uses a deep neural network to characterize the three-dimensional local structure environment of antibody amino acid residues and the amino acid sequence, and establishes a model; b. a sequence design stage, which uses the model to iteratively optimize the amino acid sites of each CDR region by inputting the main chain structure of the target antibody. In each iteration process, the model adjusts the amino acid type according to the previous update result, gradually converges the CDR region amino acid sequence that meets the target structure and functional requirements, and completes the sequence design of the antibody. The application combines the advantages of main chain design and protein language model, focuses on the amino acid sequence design of the antibody CDR region, and significantly improves the design accuracy and functionality by introducing antigen epitope information and an iterative optimization process.

The application belongs to the field of marine biotechnology, and specifically discloses a preparation method of a long oyster insulin-like peptide receptor (ILPR) polyclonal antibody and application thereof. The method is characterized by the following steps: specific antigen epitopes of the long oyster ILPR protein are screened through bioinformatics analysis, a pET32a-ILPR recombinant plasmid is constructed and induced to express in Escherichia coli; the purified recombinant protein is used as an immunogen to immunize New Zealand white rabbits, and rabbit antisera are collected after four times of booster immunization; specific polyclonal antibodies are purified by using antigen affinity chromatography technology, and can specifically recognize the ILPR protein in long oyster tissues. The antibody prepared by the application has high specificity and sensitivity, and provides an important biological tool for studying the insulin signal transduction pathway, growth regulation and energy metabolism mechanism of long oysters.

This invention belongs to the field of biomedical technology, specifically relating to an antigenic epitope peptide combination for a broad-spectrum novel coronavirus vaccine and its application. The antigenic epitope peptide combination of this invention includes a combination of viral spike protein Epi-I antigenic epitope peptides, a combination of viral spike protein Epi-II antigenic epitope peptides, and a combination of viral spike protein Epi-III antigenic epitope peptides. These antigenic epitope peptide combinations are obtained by screening spike protein epitopes from three broad-spectrum neutralizing antibodies against SARS-CoV-2, and can induce a broad-spectrum neutralizing antibody response in the host, used for the preparation of a broad-spectrum novel coronavirus vaccine. Using the antigenic epitope peptide combination of this invention, an antigenic epitope fusion protein L9 was obtained and prepared into a vaccine. The results of the examples show that the L9 vaccine has a better neutralizing effect against SARS-CoV-2 variants than the control group of the Wuhan strain of SARS-CoV-2 spike protein RBD, exhibiting good cross-neutralization.